drugset
drugset / Trial / NCT03976076

A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients

NCT03976076 ↗

Phase 2 Terminated 16 enrolled Bio-Pharm Solutions Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients.

Timeline

Start
2020-04-15
Primary completion
2021-12-10
Completion
2021-12-10

Outcome

Outcome not reported

Stopped (Enrollment): “Difficulty with patient recruitment due to COVID-19”

Drugs

EvaluationDrugModalityDoseRoute
Subject JBPOS0101 Small molecule 15 mg/kg —

Indications

infantile spasms